BAJAJ BROKING

Notification
No new Notification messages
Ather Energy IPO is Open!
Apply for the Ather Energy IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

11677

532612

INDOCO

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

INDOCO REMEDIES LTD. performance

Today’s low

Today’s high

₹ 223.48 ₹ 235.79
₹ 232.57

52 week low

52 week high

₹ 190.00 ₹ 387.55
₹ 232.57

Open Price

₹ 227.85

Prev. Close

₹ 226.69

Volume (Shares)

32762.00

Total traded value

₹ 76.19

Upper Circuit

₹ 272.02

Lower Circuit

₹ 181.35

info

INDOCO REMEDIES LTD. Share Price Update

As of the latest trading session, INDOCO REMEDIES LTD. share price is currently at ₹ 230.6, which is up by ₹ 3.91 from its previous closing. Today, the stock has fluctuated between ₹ 223.48 and ₹ 235.79. Over the past year, INDOCO REMEDIES LTD. has achieved a return of -28.86 %. In the last month alone, the return has been -4.90 %. Read More...

INDOCO REMEDIES LTD. fundamentals


  • Market cap (Cr)

    2,125.72

  • P/E Ratio (TTM)

    38.94

  • Beta

    0.69

  • Book Value / share

    123.75

  • Return on equity

    10.83%

  • EPS (TTM)

    4.22

  • Dividend yield

    0.64%

  • Net profit/quarter (Cr)

    -10.23

info icon alternate text
  • Market cap (Cr)

    2,114.19

  • P/E Ratio (TTM)

    38.94

  • Beta

    0.62

  • Book Value / share

    123.75

  • Return on equity

    10.83%

  • EPS (TTM)

    4.22

  • Dividend yield

    0.64%

  • Net profit/quarter (Cr)

    -10.23

info icon alternate text

INDOCO REMEDIES LTD. Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 364.91
Operating Expense 391.59
Net Profit -10.23
Net Profit Margin (%) -2.80
Earnings Per Share (EPS) -1.11
EBITDA 25.39
Effective Tax Rate (%) 23.42
Particulars SEP 2024 (Values in Cr)
Revenue 394.58
Operating Expense 383.34
Net Profit 12.79
Net Profit Margin (%) 3.24
Earnings Per Share (EPS) 1.39
EBITDA 57.07
Effective Tax Rate (%) 26.40
Particulars JUN 2024 (Values in Cr)
Revenue 394.22
Operating Expense 385.44
Net Profit 14.95
Net Profit Margin (%) 3.79
Earnings Per Share (EPS) 1.62
EBITDA 55.09
Effective Tax Rate (%) 23.37
Particulars MAR 2024 (Values in Cr)
Revenue 435.14
Operating Expense 422.77
Net Profit 37.56
Net Profit Margin (%) 8.63
Earnings Per Share (EPS) 4.08
EBITDA 81.14
Effective Tax Rate (%) 19.22
Particulars DEC 2023 (Values in Cr)
Revenue 448.38
Operating Expense 416.76
Net Profit 20.01
Net Profit Margin (%) 4.46
Earnings Per Share (EPS) 2.17
EBITDA 60.01
Effective Tax Rate (%) 25.94
Particulars MAR 2024 (Values in Cr)
Revenue 1761.95
Operating Expense 1657.62
Net Profit 116.64
Net Profit Margin (%) 6.61
Earnings Per Share (EPS) 12.66
EBITDA 278.02
Effective Tax Rate (%) 23.87
Particulars MAR 2023 (Values in Cr)
Revenue 1638.13
Operating Expense 1477.43
Net Profit 141.36
Net Profit Margin (%) 8.62
Earnings Per Share (EPS) 15.34
EBITDA 287.22
Effective Tax Rate (%) 26.21
Particulars MAR 2022 (Values in Cr)
Revenue 1502.70
Operating Expense 1305.81
Net Profit 154.52
Net Profit Margin (%) 10.28
Earnings Per Share (EPS) 16.77
EBITDA 329.32
Effective Tax Rate (%) 34.58
Particulars MAR 2021 (Values in Cr)
Revenue 1217.38
Operating Expense 1112.07
Net Profit 92.39
Net Profit Margin (%) 7.58
Earnings Per Share (EPS) 10.03
EBITDA 226.69
Effective Tax Rate (%) 29.66
Particulars MAR 2020 (Values in Cr)
Revenue 1079.39
Operating Expense 1079.72
Net Profit 24.25
Net Profit Margin (%) 2.24
Earnings Per Share (EPS) 2.63
EBITDA 125.77
Effective Tax Rate (%) 15.53
Particulars MAR 2024 (Values in Cr)
Book Value / Share 120.40
ROE % 9.07
ROCE % 10.76
Total Debt to Total Equity 0.47
EBITDA Margin 14.62
Particulars MAR 2023 (Values in Cr)
Book Value / Share 111.58
ROE % 14.72
ROCE % 16.74
Total Debt to Total Equity 0.30
EBITDA Margin 17.29
Particulars MAR 2022 (Values in Cr)
Book Value / Share 98.17
ROE % 18.50
ROCE % 22.08
Total Debt to Total Equity 0.31
EBITDA Margin 21.40
Particulars MAR 2021 (Values in Cr)
Book Value / Share 83.45
ROE % 12.85
ROCE % 15.06
Total Debt to Total Equity 0.36
EBITDA Margin 18.31
Particulars MAR 2020 (Values in Cr)
Book Value / Share 73.75
ROE % 3.60
ROCE % 5.60
Total Debt to Total Equity 0.42
EBITDA Margin 11.35
Particulars MAR 2024 (Values in Cr)
Book Value / Share 122.22
ROE % 10.83
ROCE % 12.31
Total Debt to Total Equity 0.39
EBITDA Margin 15.52
Particulars MAR 2023 (Values in Cr)
Book Value / Share 111.45
ROE % 14.64
ROCE % 16.66
Total Debt to Total Equity 0.31
EBITDA Margin 17.23
Particulars MAR 2022 (Values in Cr)
Book Value / Share 98.13
ROE % 18.47
ROCE % 22.05
Total Debt to Total Equity 0.31
EBITDA Margin 21.39
Particulars MAR 2021 (Values in Cr)
Book Value / Share 83.44
ROE % 12.75
ROCE % 14.99
Total Debt to Total Equity 0.36
EBITDA Margin 18.28
Particulars MAR 2020 (Values in Cr)
Book Value / Share 73.81
ROE % 3.62
ROCE % 5.61
Total Debt to Total Equity 0.42
EBITDA Margin 11.37
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 24.32
Total Assets 2144.72
Total Liabilities 2144.72
Total Equity 1110.49
Share Outstanding 92182205
Price to Book Ratio 2.69
Return on Assets (%) 4.59
Return on Capital (%) 5.58
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 13.33
Total Assets 1658.19
Total Liabilities 1658.19
Total Equity 1028.25
Share Outstanding 92150355
Price to Book Ratio 2.92
Return on Assets (%) 8.57
Return on Capital (%) 10.59
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 19.77
Total Assets 1486.09
Total Liabilities 1486.09
Total Equity 904.64
Share Outstanding 92150355
Price to Book Ratio 3.84
Return on Assets (%) 10.41
Return on Capital (%) 13.47
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 14.33
Total Assets 1315.06
Total Liabilities 1315.06
Total Equity 768.99
Share Outstanding 92150355
Price to Book Ratio 3.46
Return on Assets (%) 7.07
Return on Capital (%) 9.05
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 37.93
Total Assets 1271.59
Total Liabilities 1271.59
Total Equity 679.56
Share Outstanding 92150355
Price to Book Ratio 2.84
Return on Assets (%) 1.89
Return on Capital (%) 2.73
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 16.93
Total Assets 1960.60
Total Liabilities 1960.60
Total Equity 1126.61
Share Outstanding 92182205
Price to Book Ratio 2.69
Return on Assets (%) 5.94
Return on Capital (%) 7.18
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 12.39
Total Assets 1659.67
Total Liabilities 1659.67
Total Equity 1027.02
Share Outstanding 92150355
Price to Book Ratio 2.92
Return on Assets (%) 8.51
Return on Capital (%) 10.54
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 19.20
Total Assets 1487.56
Total Liabilities 1487.56
Total Equity 904.30
Share Outstanding 92150355
Price to Book Ratio 3.84
Return on Assets (%) 10.38
Return on Capital (%) 13.45
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 14.05
Total Assets 1316.56
Total Liabilities 1316.56
Total Equity 768.92
Share Outstanding 92150355
Price to Book Ratio 3.46
Return on Assets (%) 7.01
Return on Capital (%) 8.99
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 37.64
Total Assets 1272.31
Total Liabilities 1272.31
Total Equity 680.16
Share Outstanding 92150355
Price to Book Ratio 2.84
Return on Assets (%) 1.90
Return on Capital (%) 2.75
Particulars MAR 2024 (Values in Cr)
Net Income 124.27
Cash from Operations 174.65
Cash from Investing -433.82
Cash from Financing 280.43
Net change in Cash 3.30
Free Cash Flow 601.95
Particulars MAR 2023 (Values in Cr)
Net Income 192.79
Cash from Operations 240.48
Cash from Investing -208.17
Cash from Financing 22.80
Net change in Cash -6.54
Free Cash Flow 447.73
Particulars MAR 2022 (Values in Cr)
Net Income 236.57
Cash from Operations 214.90
Cash from Investing -121.40
Cash from Financing -44.37
Net change in Cash 8.04
Free Cash Flow 340.23
Particulars MAR 2021 (Values in Cr)
Net Income 131.99
Cash from Operations 101.94
Cash from Investing -66.69
Cash from Financing -29.87
Net change in Cash -14.34
Free Cash Flow 178.78
Particulars MAR 2020 (Values in Cr)
Net Income 28.57
Cash from Operations 126.60
Cash from Investing -55.93
Cash from Financing -63.94
Net change in Cash 2.96
Free Cash Flow 185.06
Particulars MAR 2024 (Values in Cr)
Net Income 141.69
Cash from Operations 194.36
Cash from Investing -301.70
Cash from Financing 122.40
Net change in Cash -2.51
Free Cash Flow 373.39
Particulars MAR 2023 (Values in Cr)
Net Income 191.59
Cash from Operations 240.17
Cash from Investing -208.51
Cash from Financing 22.80
Net change in Cash -6.91
Free Cash Flow 429.56
Particulars MAR 2022 (Values in Cr)
Net Income 236.23
Cash from Operations 214.53
Cash from Investing -121.41
Cash from Financing -44.36
Net change in Cash 7.77
Free Cash Flow 339.86
Particulars MAR 2021 (Values in Cr)
Net Income 131.35
Cash from Operations 101.92
Cash from Investing -66.69
Cash from Financing -29.82
Net change in Cash -14.35
Free Cash Flow 178.77
Particulars MAR 2020 (Values in Cr)
Net Income 28.70
Cash from Operations 126.57
Cash from Investing -55.94
Cash from Financing -63.94
Net change in Cash 2.76
Free Cash Flow 185.03
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 21.96 6.19 279.41 34.11 / 77.70
AMRUTAJAN HEALTH LTD 692.80 40.61 6.72 2002.93 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8665.50 129.24 31.88 21663.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 119.00 15.45 1.22 1253.91 92.25 / 184.95

INDOCO REMEDIES LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
232.57 2.59 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 232.70
  • 26 Days 236.70
  • 10 Days 234.70
  • 50 Days 243.80
  • 12 Days 235.20
  • 100 Days 263.60
  • 20 Days 236.00
  • 200 Days 288.70
228.46 PIVOT

First Support

223.22

First Resistance

231.93

Second Support

219.75

Second Resistance

237.17

Third Support

214.51

Third Resistance

240.64

RSI

47.01

ADX

16.84

MACD

-1.56

Williams % R

-62.75

Commodity Channel Index (CCI)

-83.39

Date

2025-04-30

Week

24049.00

Same Day

15084.00

Month

22880.00

1 Year

0.70

3 Year

0.74

Over 1 Month

-4.90%

down

Over 1 Year

-28.86%

down

Over 3 Months

-5.13%

down

Over 3 Years

-14.58%

down

Over 6 Months

-24.40%

down

Over 5 Years

-0.09%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

INDOCO REMEDIES LTD. shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
21.1%
Promoter Holdings
58.89%
FII
1.24%
DII
18.75%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Spa Holdings Pvt Ltd 1.8335E7 (19.88%) Shareholding of Promoter and Promoter Group
Shanteri Investment Pvt Ltd 1.5858805E7 (17.19%) Shareholding of Promoter and Promoter Group
Panandikar Aditi Milind 5663795.0 (6.14%) Shareholding of Promoter and Promoter Group
Madhura Suresh Kare 5239650.0 (5.68%) Shareholding of Promoter and Promoter Group
Kare Aruna Suresh 4794714.0 (5.2%) Shareholding of Promoter and Promoter Group
Nippon Life India Trustee Ltd-a/c Nippon India Small Cap Fund 4429483.0 (4.8%) Public Shareholding
Quant Mutual Fund - Quant Small Cap Fund 4199230.0 (4.55%) Public Shareholding
Kare Suresh Govind 4060408.0 (4.4%) Shareholding of Promoter and Promoter Group
Dsp Healthcare Fund 3668295.0 (3.98%) Public Shareholding
Franklin India Smaller Companies Fund 2025592.0 (2.2%) Public Shareholding
Hdfc Value Fund 1543378.0 (1.67%) Public Shareholding
Tata India Pharma & Healthcare Fund 1220498.0 (1.32%) Public Shareholding
Mangeshi Investment Private Limited 1167300.0 (1.27%) Public Shareholding
Suresh Govind Kare Huf (karta- Suresh Govind Kare) 273500.0 (0.3%) Shareholding of Promoter and Promoter Group
Sharda Ramnath Kare 32500.0 (0.04%) Shareholding of Promoter and Promoter Group
Pratima Ajit Vaidya 26550.0 (0.03%) Shareholding of Promoter and Promoter Group
Rohan Anup Ramani 7300.0 (0.01%) Shareholding of Promoter and Promoter Group
Mahika Milind Panandikar 7800.0 (0.01%) Shareholding of Promoter and Promoter Group
Milind S Panandikar 7500.0 (0.01%) Shareholding of Promoter and Promoter Group
Megh Milind Panandikar 13000.0 (0.01%) Shareholding of Promoter and Promoter Group
Pooja Rajendra Pai 10767.0 (0.01%) Shareholding of Promoter and Promoter Group
Ramnath Govind Kare 2000.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

INDOCO REMEDIES LTD. corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
18 Sep 2023 2.25 Final 19 Sep 2023 Equity shares
14 Sep 2022 1.5 Final 15 Sep 2022 Equity shares
14 Sep 2022 0.75 Special 16 Sep 2022 Equity shares
17 Sep 2021 1.5 Final 21 Sep 2021 Equity shares
18 Sep 2020 0.3 Final 22 Sep 2020 Equity shares
22 Aug 2019 0.3 Final 26 Aug 2019 Equity shares
31 Aug 2018 1.0 Final 04 Sep 2018 Equity shares
31 Jul 2017 1.6 Final 02 Aug 2017 Equity shares
20 Jul 2016 0.2 Final 22 Jul 2016 Equity shares
17 Mar 2016 1.4 Interim 18 Mar 2016 Equity shares
21 Jul 2015 1.6 Final 23 Jul 2015 Equity shares
21 Jul 2014 1.4 Final 23 Jul 2014 Equity shares
19 Jul 2013 1.1 Final 23 Jul 2013 Equity shares
20 Jul 2012 1.1 Final 24 Jul 2012 Equity shares
19 Jul 2011 8.0 Final 21 Jul 2011 Equity shares
13 Jul 2010 7.0 Final 15 Jul 2010 Equity shares
09 Sep 2009 2.0 Final 11 Sep 2009 Equity shares
11 Dec 2008 3.25 Interim 12 Dec 2008 Equity shares
19 Sep 2008 5.0 Final 23 Sep 2008 Equity shares
13 Dec 2007 6.5 Final 15 Dec 2007 Equity shares
15 Sep 2005 0.0 Final 17 Sep 2005 Equity shares
Ex-Date Ex-Bonus Ratio
17 May 2012 17 May 2012 1:2
Ex-Date Old FV NEW FV Record Date
17 May 2012 10.0 2.0 19 May 2012
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
18 Sep 2023 2.25 Final 19 Sep 2023 Equity shares
14 Sep 2022 1.5 Final 15 Sep 2022 Equity shares
14 Sep 2022 0.75 Special 16 Sep 2022 Equity shares
17 Sep 2021 1.5 Final 21 Sep 2021 Equity shares
18 Sep 2020 0.3 Final 22 Sep 2020 Equity shares
22 Aug 2019 0.3 Final 26 Aug 2019 Equity shares
31 Aug 2018 1.0 Final 04 Sep 2018 Equity shares
31 Jul 2017 1.6 Final 02 Aug 2017 Equity shares
20 Jul 2016 0.2 Final 22 Jul 2016 Equity shares
17 Mar 2016 1.4 Interim 18 Mar 2016 Equity shares
21 Jul 2015 1.6 Final 23 Jul 2015 Equity shares
21 Jul 2014 1.4 Final 23 Jul 2014 Equity shares
19 Jul 2013 1.1 Final 23 Jul 2013 Equity shares
20 Jul 2012 1.1 Final 24 Jul 2012 Equity shares
19 Jul 2011 8.0 Final 21 Jul 2011 Equity shares
13 Jul 2010 7.0 Final 15 Jul 2010 Equity shares
09 Sep 2009 2.0 Final 11 Sep 2009 Equity shares
11 Dec 2008 3.25 Interim 12 Dec 2008 Equity shares
19 Sep 2008 5.0 Final 23 Sep 2008 Equity shares
13 Dec 2007 6.5 Final 15 Dec 2007 Equity shares
15 Sep 2005 0.0 Final 17 Sep 2005 Equity shares
Ex-Date Ex-Bonus Ratio
17 May 2012 17 May 2012 1:2
Ex-Date Old FV NEW FV Record Date
17 May 2012 10.0 2.0 19 May 2012

INDOCO REMEDIES LTD. Share Price

Indoco Remedies Limited, incorporated on August 23, 1947 is a Mumbai-based pharmaceutical company focused on formulations, with some presence in contract manufacturing and research. The Company headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries. The Company is engaged in the manufacturing and marketing of pharmaceutical Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs).

Indoco, a USD 212 million company has 11 manufacturing facilities, 7 of which are for FDFs and 4 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility.

Currently, Indoco has a presence in therapeutic segments including anti-infective, anti-cold preparation, opthalmic, antispasmodic, stomatology, anti-inflammatory and anti-fungal. As per AC Nielsen ORG-MARG market survey (August 2004) of doctors, Indoco ranked first in the stomatology, ninth in the opthalmic and twelve in the pediatric segments in terms of prescription generation in the domestic market. In the overall pharma industry, Indoco is ranked 34th as per AC Nielsen ORG-MARG Retail Audit, but ranked 23rd in terms of prescription generation, indicating the strength of its marketing network. Further, the company last year launched a new super specialty division, with focus on diabetic and cardio-vascular segments. Its entry into the lifestyle segment with a strong presence in the prescription segment would augur well for the higher- than-average industry growth.

Currently, Indoco has 4 manufacturing facilities. Two are located in Mumbai and two in Goa, and an R&D centre in Mumbai. The solid dosage facility in Goa has been accredited by UK-Medicines and Healthcare Products Regulatory Agency (MHRA), and the sterile plant of Goa has been designed as per US Food and Drug Administration (FDA) norms. On the selling front, it has a marketing network of 1,248 medical representatives.

In July 2014, the Company purchased the remaining shares of its subsidiary, Xtend Industrial Designers and Engineers Private Limited to make it a 100% subsidiary of the Company.

In April 2015, the Company acquired from Piramal Enterprise Limited, their Clinical Research Division, located in Hyderabad. The division is equipped with a 98-bed facility, including a four-bed ICU, state-of-the-art analytical lab and capabilities of eCTD submission. It also has GCP certification from UK-MHRA and also has regulatory approvals from several bodies including USFDA. The acquisition would reduce the Company's dependability to outsource bio-equivalence studies. This will not only reduce cost but also ensure time-bound outcome of studies and add pace to the Company's existing R&D efforts.

In December, 2015, the Company incorporated Indoco Remedies Singapore Pte Limited, a 100% subsidiary. The subsidiary will be used for the expansion of the company's ambitious plans to extend its activities in the European and US markets. The company has the following 3 subsidiary companies as on 31 March 2016.i. Xtend Industrial Designers and Engineers Private Limited,ii. Indoco Pharmchem Limited,iii. Indoco Remedies Singapore Pte. Ltd.

During the year 2017-18, the Company (F&D) was granted two patents by the Indian Patent Office and one by United States Patents Office for formulation of Olopatadine, Gliclazide, and Brinzolamide respectively. The Company was also granted three patents by Indian Patents Office for manufacturing processes of three APIs, viz., Febuxostat, Rufinamide and Lacosamide.

Indoco's R&D efforts received due recognition with the Best Process Patent Award for the year 2016-2017' forfive Indian patents granted related to Processforthe preparation of Tapentadol', Process for the preparation of Aminoindane compound', Process for preparation of Pyrazole derivatives', Preparation of phenylacetic acid derivative' and Preparation of Substituted 1H-imidazo[4,5-c] quinoline'. This award was presented at Indian Drug Manufacturers Association's 56th Annual Day celebrations held on 20 January 2018.

100% subsidiary known as Indoco Remedies Singapore Pte Ltd. was set up in the Czech Republic effective from April 9, 2019.

In August'21, Company received GCP & GLP Accreditation from the UK-MHRA (Medicines and Healthcare Products Regulatory Agency) for its Clinical Research Division - AnaCipher, located at Hyderabad. The Company launched six new products (SKUs), two in the acute segment, Naricover and Dropizin Syrup, one in the chronic segment, Methycal 60 K and three in the sub-chronic segment, Rexidin SRS, Noxa and Subitral in the domestic market in 2022.

In 2023, Company acquired 85% equity stake in the US based FPP Holding Company, LLC for USD 4 million from Contract Pharmacal Corp. (CPC). Warren Remedies Private Limited a wholly owned subsidiary of the Company, was incorporated in 2022-23 for setting up a unit for manufacturing of pharmaceutical products both formulations as well as Active Pharmaceutical Ingredients (API). The Company acquired 26% equity stake each in Kanakal Wind Energy Private Limited and Jalansar Wind Energy Private Limited, representing 8,64,000 equity shares of Rs 10/- each and 5,76,000 equity shares of Rs 10/- each respectively, for setting up Solar Power Plant at Akkalkot, Solapur District, Maharashtra.

Parent organization Indian Private
NSE symbol INDOCO
Founded 1947
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Indoco Remedies Ltd?

Answer Field

The share price of Indoco Remedies Ltd for NSE is ₹ 230.6 and for BSE is ₹ 229.35.

What is the Market Cap of Indoco Remedies Ltd?

Answer Field

The market cap of Indoco Remedies Ltd for NSE is ₹ 21,25.72 Cr. and for BSE is ₹ 21,14.19 Cr. as of now.

What is the 52 Week High and Low of Indoco Remedies Ltd?

Answer Field

The 52 Week High and Low of Indoco Remedies Ltd for NSE is ₹ 387.55 and ₹ 190.00 and for BSE is ₹ 385.50 and ₹ 190.00.

How to Buy Indoco Remedies Ltd share?

Answer Field

You can trade in Indoco Remedies Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Indoco Remedies Ltd?

Answer Field

The 1 year returns on the stock has been -28.86%.

What is the Current Share Price of Indoco Remedies Ltd?

Answer Field

Indoco Remedies Ltd share price is for NSE ₹ 230.6 & for BSE ₹ 229.35 as on Apr 30 2025 03:29 PM.

What is the Market Cap of Indoco Remedies Ltd Share?

Answer Field

The market cap of Indoco Remedies Ltd for NSE ₹ 21,25.72 & for BSE ₹ 21,14.19 as on Apr 30 2025 03:29 PM.

What is the P/E Ratio of Indoco Remedies Ltd Share?

Answer Field

As on Apr 30 2025 03:29 PM the price-to-earnings (PE) ratio for Indoco Remedies Ltd share is 38.94.

What is the PB ratio of Indoco Remedies Ltd Share?

Answer Field

As on Apr 30 2025 03:29 PM, the price-to-book (PB) ratio for Indoco Remedies Ltd share is 123.75.

How to Buy Indoco Remedies Ltd Share?

Answer Field

You can trade in Indoco Remedies Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Indoco Remedies Ltd Share on Bajaj Broking App?

Answer Field

To buy Indoco Remedies Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Indoco Remedies Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|